Genenta Science S.p.A. (GNTA)
| Market Cap | 23.59M -65.8% |
| Revenue (ttm) | n/a |
| Net Income | -7.67M |
| EPS | -0.39 |
| Shares Out | 23.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 58,845 |
| Open | 1.020 |
| Previous Close | 0.991 |
| Day's Range | 1.000 - 1.080 |
| 52-Week Range | 0.550 - 10.000 |
| Beta | 0.77 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 24, 2026 |
About GNTA
Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/m... [Read more]
News
Sophia unveils Roman robotic arm to inspect nuclear fusion machine operations
Sophia High Tech, backed by Genenta Science (GNTA), announced the unveiling of Roman, a robotic arm engineered to perform inspection and maintenance operations inside a nuclear fusion machine. Sophia ...
Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm
MILAN and NAPLES, Italy, July 23, 2026 (GLOBE NEWSWIRE) -- Sòphia High Tech S.r.l. (Sòphia HT), an Italian aerospace and defense company manufacturing critical parts for Europe's space and defense pro...
Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results
Fiscal Year 2025 Highlights FY2025 sales rose 29.3% to €7.17 million; total value of production increased 34.7% to €8.47 million EBITDA grew 68.1% to €1.61 million, expanding the EBITDA margin by appr...
Genenta signs Definitive Agreements with Sophia High Tech
Genenta signs Definitive Agreements with Sophia High Tech Genenta enters aerospace as it continues its strategic transformation into a next-generation ind
Genenta Science enters binding offer to fund Sophia High Tech
Genenta Science (GNTA) announced that it has entered into a binding offer with Sophia High Tech, under which Genenta will fund Sophia through two reserved capital increases, with the goal…
Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
MILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian n...
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
Focused on selective acquisitions of high-quality companies in strategic industrial sectors Focused on selective acquisitions of high-quality companies in strategic industrial sectors
Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University
MILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN)1, a strategic industrial consolidator focused on biotech, defense, aerospac...
Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform
MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge (Nasdaq: SAEN), a strategic industrial consolidator focused on biotech, defense, aeros...
Genenta Science to change name to Saentra Forge, seeks controlling stake in ATC
Genenta Science (GNTA) intends to target majority ownership in companies with established operating profitability, typically generating up to approximately EUR 5M in EBITDA. In this context, Genenta p...
Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator
Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian Companies ATC - a Defense-Sector Company: First Industr...
Genenta Science Provides Update on CEO Ownership
MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, p...
Genenta Science provides update from TEM-GBM study
Genenta Science (GNTA) announced an update from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme patients with an unmethylated MGMT gene promoter. As of the November 21, data cut,…
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeuti...
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with instit...
Why Is Genenta Science Stock (GNTA) Up 275% Today?
Genenta Science stock surged on Friday after it announced an expanded strategic partnership.
Genenta Science, Anemocyte enter pact to advance Plasmid DNA technology
Genenta Science (GNTA) and Anemocyte announced a strategic collaboration with a focus on off-the-shelf lentiviral vector Plasmid DNA technology platform. This new agreement builds and expands on the e...
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production
MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...
Genenta Science announces follow-up observations in glioblastoma study
Genenta Science (GNTA) announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme study, with 25 patients receiving Temferon. Two patients have been enrolled in the...
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
MILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a total of 38 patients were enrolled in newly diagnosed gliobla...
Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference
Milan, Italy and New York, New York--(Newsfile Corp. - May 8, 2025) - Genenta Science, SpA (NASDAQ: GNTA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking...
Genenta Science, Anemocyte announce collaboration
Genenta Science (GNTA) announced a collaboration with Anemocyte. This strategic partnership marks a major milestone, encompassing the successful production of critical starting materials, including th...
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyt...
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Mo...
Genenta Science announces EUR 20M financing to expand pipeline
Genenta announced a EUR 20M financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical to support the expansion of its pipeline by advancing Temferon in…